PeptideStack
5.2kquestions
20kanswers
220users

How many vials from an ERP lot should I send for peptide mapping?

Asked 22 Mar 2026Modified 2 months agoViewed 2.9k times
5

For reference: ERP · peptide mapping.

The units are where I keep going wrong, so please be explicit about them.

I have sanity-checked the order of magnitude and it seems right, which is not the same as being right.

Where is my error, and what is the correct working?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
peptide-mapping
peptide-mapping

Enzymatic digestion followed by LC-MS/MS to confirm sequence rather than just mass. The method that catches a scrambled sequence or a D-amino-acid…

103 questions
shareeditfollowflag
LW
askedlinnea_wahlberg17k2722 Mar 2026

5 Answers

Accepted answer first, then by votes
23

Accepted answer

To be exact about it, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
TA
answered · acceptedtri_gly_ala24k3828 Mar 2026
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
7

Mechanically, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

The part that matters: if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
TM
answeredtobias_maartens171k3589 Apr 2026
7

To be exact about it, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
RP
answeredretest_please9.7k1520 Apr 2026
The system-suitability data is the part that tells you whether to believe the rest. – laminar_bench 8 months ago
2Thank you — this is the answer I was looking for. – net_peptide 9 months ago
add a comment
5

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
WO
answeredw_okoye43k1371 May 2026
3Does this hold for a longer chain length, where the deletion sequences accumulate? – elke_brunner 3 months ago
add a comment
5

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
CL
answeredcap_the_luer14k2712 Jun 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.